PMID- 9729542
OWN - NLM
STAT- MEDLINE
DCOM- 19981022
LR  - 20210526
IS  - 1071-412X (Print)
IS  - 1098-6588 (Electronic)
IS  - 1071-412X (Linking)
VI  - 5
IP  - 5
DP  - 1998 Sep
TI  - Immune response against the exp-1 protein of Plasmodium falciparum results in 
      antibodies that cross-react with human T-cell lymphotropic virus type 1 proteins.
PG  - 721-4
AB  - To examine the role of the Plasmodium falciparum Exp-1 blood-stage protein in 
      producing antibodies that cross-react with human T-cell lymphotropic virus type I 
      (HTLV-I) proteins, we studied sera from Indonesian volunteers who seroconverted 
      to malaria after transmigrating to an area where malaria is hyperendemic. Samples 
      from Philippine volunteers, that were used in a prior study that examined malaria 
      antibodies that cross-react with HTLV-I proteins, were also used. Eighty-three 
      percent of the Indonesian transmigrants developed antibodies against the malaria 
      Exp-1 protein by 6 months postmigration. Of these malaria seroconverters, 27% 
      developed false-positive HTLV-I enzyme immunoassay (EIA) immunoreactivity, as 
      indicated by indeterminate HTLV-I Western blot banding patterns. Five of the six 
      Philippine samples tested were HTLV-I EIA false positive and Western blot 
      indeterminate. When a recombinant Exp-1 protein was used in blocking experiments, 
      the HTLV-I Western blot immunoreactivity of sera from both groups was either 
      completely eliminated or greatly reduced. No effect on the Western blot 
      immunoreactivity of truly HTLV-I-positive sera was seen. To determine if 
      immunization with the recombinant Exp-1 protein could elicit the production of 
      HTLV-I antibodies, six mice were inoculated with the recombinant protein. 
      Following administration of three 50-microgram doses of the protein, four of the 
      six mice developed antibodies that cross-reacted with HTLV-I proteins on Western 
      blot. These results indicate that the immune response against the malaria Exp-1 
      protein may result in HTLV-I-cross-reacting antibodies that can lead to 
      false-positive EIA and indeterminant Western blotting results.
FAU - Porter, K R
AU  - Porter KR
AD  - Viral and Rickettsial Diseases Program, Naval Medical Research Institute, 
      Bethesda, Maryland, USA. porterkr@namru2.com
FAU - Aguiar, J
AU  - Aguiar J
FAU - Richards, A
AU  - Richards A
FAU - Sandjaya, B
AU  - Sandjaya B
FAU - Ignatias, H
AU  - Ignatias H
FAU - Hadiputranto, H
AU  - Hadiputranto H
FAU - Ridley, R G
AU  - Ridley RG
FAU - Takacs, B
AU  - Takacs B
FAU - Wignall, F S
AU  - Wignall FS
FAU - Hoffman, S L
AU  - Hoffman SL
FAU - Hayes, C G
AU  - Hayes CG
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Clin Diagn Lab Immunol
JT  - Clinical and diagnostic laboratory immunology
JID - 9421292
RN  - 0 (Antibodies, Protozoan)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Antigens, Protozoan)
RN  - 0 (HTLV-I Antibodies)
RN  - 0 (HTLV-I Antigens)
RN  - 0 (Protozoan Proteins)
RN  - 0 (QF116 antigen, Plasmodium falciparum)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Viral Proteins)
SB  - IM
MH  - Animals
MH  - Antibodies, Protozoan/blood/*immunology
MH  - Antibodies, Viral/blood/immunology
MH  - Antigens, Protozoan/*immunology
MH  - Blotting, Western
MH  - Cross Reactions/*immunology
MH  - HTLV-I Antibodies/blood
MH  - HTLV-I Antigens/*immunology
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Indonesia
MH  - Mice
MH  - Plasmodium falciparum/*immunology
MH  - Protozoan Proteins/*immunology
MH  - Recombinant Proteins/genetics/immunology
MH  - Viral Proteins/*immunology
PMC - PMC95646
EDAT- 1998/09/08 00:00
MHDA- 1998/09/08 00:01
PMCR- 1998/09/01
CRDT- 1998/09/08 00:00
PHST- 1998/09/08 00:00 [pubmed]
PHST- 1998/09/08 00:01 [medline]
PHST- 1998/09/08 00:00 [entrez]
PHST- 1998/09/01 00:00 [pmc-release]
AID - 0020 [pii]
AID - 10.1128/CDLI.5.5.721-724.1998 [doi]
PST - ppublish
SO  - Clin Diagn Lab Immunol. 1998 Sep;5(5):721-4. doi: 10.1128/CDLI.5.5.721-724.1998.